Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

25 Oct 2010
OSU's Personalized Health Care National Conference focuses on P4 Medicine

OSU's Personalized Health Care National Conference focuses on P4 Medicine

18 Oct 2010
AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO presents tivozanib Phase 2 study results at ESMO Congress

11 Oct 2010
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

11 Oct 2010
Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics reports SGN-75 phase I clinical trial data

11 Oct 2010
AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

7 Oct 2010
Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

5 Oct 2010
AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

4 Oct 2010
Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

1 Oct 2010
AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

30 Sep 2010
Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

28 Sep 2010
Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

24 Sep 2010
immatics raises EUR53.8million in Series C financing round

immatics raises EUR53.8million in Series C financing round

21 Sep 2010
FDA decides to review information on Avastin for advanced HER2-negative breast cancer

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

18 Sep 2010
JVIR supplement to review thermal ablation usage in treating cancer

JVIR supplement to review thermal ablation usage in treating cancer

27 Aug 2010
Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

24 Aug 2010
AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

12 Aug 2010
Surgeons continue to advance minimally-invasive surgery for kidney cancer patients

Surgeons continue to advance minimally-invasive surgery for kidney cancer patients

30 Jul 2010
Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

29 Jul 2010
AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

29 Jul 2010

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback